Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK’s CMA Fines Four On Nortriptyline

Accord, Alissa, Lexon And King Fined Over £3.4m In Total

Executive Summary

Four firms – Accord, Alissa, Lexon and King – have been fined by the UK’s Competition and Markets Authority over price-fixing and information-sharing activities related to the supply of nortriptyline.

You may also be interested in...



UK Court Declines To Back Phenytoin Fines

A UK appeals court has provided detailed guidance on how the country’s Competition and Markets Authority should evaluate unfair pricing, as part of a ruling that upholds a previous decision to overturn CMA fines of almost £90m ($112m) imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.

Two Admit Collusion On UK Nortriptyline

Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.

Aspen Will Pay UK's NHS £8m In Landmark Deal Following Competition Probe

Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel